Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.

Maria K HordinskyAdelaide A HebertMelinda J GooderhamOhsang KwonNikolay MurashkinHong FangKazutoshi HaradaErnest LawDalia WajsbrotLiza TakiyaSamuel H ZwillichRobert WolkHelen Tran

Published in: Pediatric dermatology (2023)

Ritlecitinib treatment demonstrated clinician-reported efficacy, patient-reported improvement, and an acceptable safety profile through Week 48 in adolescents with AA with ≥50% scalp hair loss.

Keyphrases

double blind
placebo controlled
patient reported
young adults
clinical trial
phase iii
physical activity
phase ii
study protocol
randomized controlled trial
open label